Report: Orphan drugs to nab 19% of drug sales by 2020–if payers don’t balk, that is

Carly Helfand

Pharma companies have been quick to get on board with the development trend in recent years, racing to bring pricey treatments for small patient populations to market. And that trend won't be going out of style anytime soon, a new says.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS